Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Improving second-line treatments in DLBCL

Keith Wilson • 4 Apr 2022
BSH 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Keith Wilson, MBBS, FRCP, FRCPath, Cardiff University, Cardiff and Vale University Health Board, Cardiff, Wales, briefly explains the need to improve second-line treatment options for patients with diffuse large B-cell lymphoma (DLBCL). Dr Wilson first discusses the role of transplantation as a second-line therapy, and then emphasizes the need to improve options for patients who relapse or do not respond. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Keith Wilson

1:46
COVID-19 vaccine effectiveness in transplant patients
Keith Wilson • 4 Apr 2022
2:07
Using prehabilitation to improve patient outcome post-transplant
Keith Wilson • 4 Apr 2022
1:38
Managing post-transplant complications in patients with DLBCL
Keith Wilson • 4 Apr 2022
0:44
Autologous transplantation in DLBCL and unmet needs
Keith Wilson • 4 Apr 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals